Skip to main content
. 2023 Oct 6;14(10):652. doi: 10.1038/s41419-023-06171-7

Fig. 7. PI3K/mTOR inhibitors overcome the radioresistance of SCLC through increasing ROS production by promoting the autophagy-lysosome pathway of G6PD.

Fig. 7

A, B The protein expression of G6PD and Glut1 in SBC2 and H446RR cells treated with PI3K/mTOR inhibitors were detected by immunoblotting over time. C The mRNA level of G6PD and Glut1 in SBC2 and H446RR cells treated with PI3K/mTOR inhibitors were detected by q-PCR. D G6PD activity in SBC2 and H446RR cells treated with PI3K/mTOR inhibitors were detected. E G6PD expression in different groups was determined by immunoblotting. F Ribulose 5-phosphate and ribose 5-phosphate level were detected across different groups. G The expression of G6PD in cells treated with CHX (100 μg/ml for 6 h) or CHX + MG132 (10 μM for 6 h) were detected using immunoblotting. H The expression of G6PD, SQSTM1/p62 and LC3B II/I in cells treated with either IR alone, IR + PI3K/mTOR inhibitors, or IR + PI3K/mTOR inhibitors+CQ was detected by immunoblotting. I The half-life of G6PD protein in cells treated with either CHX alone, CHX + GSK2126458, or CHX + GSK2126458 + CQ was detected by immunoblotting. J The interaction between HSPA8/HSC70 and G6PD in SBC2 cells were validated by Co-IP assay.